DaVita Reaches New 52-Week High (DVA)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- DaVita (NYSE: DVA) hit a new 52-week high Thursday as it is currently trading at $112.23, above its previous 52-week high of $111.34 with 365,970 shares traded as of 11:15 a.m. ET. Average volume has been 741,600 shares over the past 30 days.

DaVita has a market cap of $10.39 billion and is part of the health care sector and health services industry. Shares are up 45.8% year to date as of the close of trading on Wednesday.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 20.1, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 17.7.

  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

TheStreet Ratings rates DaVita as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full DaVita Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy It Like Buffett -- or Better

Buy It Like Buffett -- or Better